iVIEW-1201 Phase II IND clinical trial application for the Treatment of Adenoviral Conjunctivitis approved by Indian Regulatory Authority (CDSCO)

June 6, 2019

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, today announced that its Phase II clinical trial IND application of iVIEW-1201 for the Treatment of Adenoviral Conjunctivitis has been approved by Indian Regulatory Authority, CDSCO.

Dr. Bo Liang, Chairman & President of iVIEW and Dr. Vijai Kumar, President & CMO of Excel Life Sciences have attended the Subject Expert Committee (SEC) meeting on 06/Jun’19 at Indian FDA and received positive recommendations from SEC. Excel Life Sciences, iVIEW's partner for conducting studies in India, is expecting the written approval for study from Drug Controller General of India (DCGI) by July. According to Dr. Liang, "we are excited about the fast approval for the study in India and look forward to starting the trial and enrolling patients soon. We believe that iVIEW-1201 will be the first FDQ approved sustained release broad spectrum antiseptic formulation, which will bring significant value to patients as there is no approved treatment for viral conjunctivitis currently. This is an exciting development for iVIEW." Dr. Kumar commented, “We believe Excel expertise in conducting conjunctivititis trials in India will help the successful trial execution of the phase II trials and speed up the process for market approval.”[…]

iVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

April 11, 2019

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of $300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). This phase I SBIR Year 2 grant is awarded based on iVIEW’s successful completion of its Year 1 project since April 1, 2018. iVIEW's project is titled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis”. “If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)", commented by the NIH reviewers. Dr. Bo Liang, Chairman & President at iVIEW comments, "The continuation of SBIR award showed the confidence of the agency towards our innovation and project progress. In the Grant Year 2 period, we will progress quickly though pre-clinical studies and plan to file US IND in the year of 2020 to move into clinical development."[…]

iVIEW-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA

December 31, 2018

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that its Phase II clinical trial IND application of iVIEW-1201 was been accepted by US FDA. As Dr. Wendy Streight, FDA Regulatory Project Manager, said in her email, “just to confirm, yes, your study is safe to proceed.”

In the pre-IND meeting response from FDA, FDA responded “A phase I safety/tolerability study is not needed for this drug product. There is adequate safety data available to proceed with dose ranging/efficacy studies.” Also FDA stated that “A drug vs. placebo pivotal trial for acute viral conjunctivitis is acceptable.”[…]

iVIEW Therapeutics Closes its A round financing to move forward iVIEW-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis

June 27, 2018

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, dermatology and otolaryngology, today announced that it has closed its A round financing of close to $6 million dollars from both strategic and reputable venture investors including Zhejiang Huahai Pharmaceutical Co., Ltd., Shenzhen Share Precision Medical LLP and Alpha Bioventure LLC.

Dr. Bo Liang, President & Director at iVIEW comments, "I am glad that the investors has confidence on iVIEW’s sustain release drug delivery technology platform and iVIEW-1201’s potential as first-line treatment of viral conjunctivitis. The A round financing will allow the company to move our lead compound, iVIEW-1201 into phase II clinical trials in 2019.” “We are happy to lead this round of investment into iVIEW Therapeutics, as we are not only attracted by the potential of iVIEW-1201, a long acting broad spectrum antiseptic, to treat acute conjunctivitis, which there is no current FDA approved treatment for viral conjunctivitis, but also impressed by the successful track record of iVIEW’s founding team to lead the company to be a successful specialty pharmaceutical company focusing on ophthalmology.” Commented by Mr. Bin He, General Manager of Huahai Investment. […]

iVIEW Therapeutics collaborates with Ophthalmology Department of Zhongshan Eye Hospital of Fudan University in Shanghai on the iVIEW-1201 phase II trials for the treatment of viral conjunctivitis

April 26, 2018

[April 26, 2018, Shanghai] Dr. Bo Liang, Chairman of iVIEW Therapeutics Inc., came to Zhongshan Eye Hospital, Shanghai to talk with Professor Fei Yuan, Chief Physician of Ophthalmology at Zhongshan Eye Hospital of Fudan University, about the collaboration for iVIEW-1201 project clinical trials in China for the treatment of viral conjunctivitis.

The Department of Ophthalmology, Zhongshan Eye Hospital, was founded in 1945 and rebuilt in 1976. The Department inherits a fine tradition and has clear advantages. It has established outstanding development in areas such as adjustable, multifocal intraocular lens implantation and phakic intraocular lens implantation, as well as clinical epidemiology. It has built up excellent academic influence in China and internationally. A large number of research papers have been resulted in original researches conducted in the hospital and published in reputable international journals.[…]

iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

March 26, 2018

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company focusing on topical drug and medical device development, today announced that it has received a Small Business Innovation Research (SBIR) Award from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). The phase I SBIR grant is awarded to iVIEW's project titled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis". "The PI proposes to develop a long acting in situ gel nasal spray containing povidone iodine in combination with budesonide for the treatment of chronic rhinosinusitis. If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)", commented by the NIH reviewers. Dr. Bo Liang, President & Director at iVIEW comments, "we will progress quickly though pre-clinical studies and move into proof-of-concept human trials with the innovative extended release formulation to achieve minimized irritation to nasal cavity with long acting therapeutic effect."[…]

iVIEW Therapeutics will present its novel sustained-release povidone iodine ophthalmic formulation for the treatment of acute conjunctivitis in TechConnect World Innovation Summit & Expo and US National Innovation Summit and National SBIR/STTR Conference

March 6, 2017

Doylestown, Pennsylvania--iVIEW Therapeutics Inc. is pleased to announce Dr. Bo Liang, President will present in 2017’s TechConnect World Innovation Summit & Expo and US National Innovation Summit and National SBIR/STTR Conference, May 15-17, 2017, just outside Washington, D.C., at the Gaylord National Resort & Convention Center, National Harbor, MD. In addition of accepted oral paper presentation scheduled at 11:55am on May 17, iVIEW was accepted to showcase the technology during the conference.

Submission Number: 2145
Technology Title: Development of a Novel in-situ Gel Povidone Iodine Ophthalmic Drop for the Treatment of Viral Conjunctivitis
http://techconnectworld.com/World2017 […]

iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s National Eye Institute

September 12, 2016

Doylestown, Pennsylvania--iVIEW Therapeutics Inc., an innovative start-up specialty pharmaceutical company focusing on topical drug and medical device development, today announced that it has received a Small Business Innovation Research (SBIR) Award from National Eye Institute(NEI) at National Institutes of Health (NIH). The phase I SBIR grant is awarded to iVIEW's project titled " Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis". "This award is a NEI's recognition of iVIEW's innovative approach to solve this unmet medical need -- viral conjunctivitis", Dr. Bo Liang, Founder & Director at iVIEW comments, "we will progress quickly though pre-clinical studies and move into proof-of-concept human trials with the innovative extended release formulation of Povidone Iodine ophthalmic drops for viral conjunctivitis." Dr. John J. Baldwin, Co-founder and Director of iVIEW, further commented, "This work is a further extention of the Founders long term interest in novel treatments for ocular diseases through improving the profile of established medicaments using extended release strategies"[…]

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2019 iVIEW Therapeutics, Inc. All rights reserved.